---
title: H209 CDX Model - TD2 Precision Oncology
description: H209 is a pivotal cell line in the study of small cell lung cancer, offering insights into the disease's aggressive biology and response to therapeutic agents.
---
×
[](https://td2inc.com/?hsLang=en)
[](https://td2inc.com/?hsLang=en)
# H209 CDX Model
The H209 cell line originates from human small cell lung cancer (SCLC), a type of lung cancer characterized by its aggressive growth and tendency for early metastasis. H209 offers an indispensable model for researchers aiming to unravel the complexities of SCLC biology, its underlying molecular pathways, and potential therapeutic interventions. This cell line mirrors many of the molecular characteristics and genetic mutations commonly associated with SCLC, further solidifying its position as a representative tool for preclinical research. The behavior of H209 in both in vitro and in vivo settings provides insights into SCLC’s rapid growth, neuroendocrine characteristics, potential for metastatic spread, and inherent responsiveness or resistance to chemotherapeutic agents. H209 is widely used by researchers seeking to delve deeper into the molecular drivers of SCLC, as well as to test and refine emerging therapeutic strategies, especially in the realm of targeted therapies and immunotherapies.
### Request Additional CDX Model Data
## CONTACT US
## Get Started.
Have questions about how TD2 can assist with your regulatory needs? Reach out to our expert staff today to get started.
[Get Started Now](https://td2inc.com/contact-us/?hsLang=en)
[](https://td2inc.com/?hsLang=en)
Office
13208 E. Shea Blvd,
Suite 100
Scottsdale, AZ 85259
Phone
(602) 358-8300
Connect with us
-
-
© 2026 Translational Drug Development. All Rights Reserved. [Terms and Conditions](https://td2inc.com/terms-and-conditions?hsLang=en) | [Privacy Policy](https://td2inc.com/privacy-policy?hsLang=en)